Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Docetaxel With Radiation in Soft Tissue Sarcoma
NCT04037527Phase 1Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine and docetaxel in soft tissue sarcoma (STS), sponsored by Wake Forest University Health Sciences. Primary endpoints: Maximum Tolerated Dose at 8 weeks and Number of Toxicity Incidences. Started Aug 2020; status: terminated.
02
Drugs
gemcitabinedocetaxel
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04037527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037527.